DK148751B - Fremgangsmaade til fremstilling af cyclosporinderivater - Google Patents
Fremgangsmaade til fremstilling af cyclosporinderivater Download PDFInfo
- Publication number
- DK148751B DK148751B DK188778AA DK188778A DK148751B DK 148751 B DK148751 B DK 148751B DK 188778A A DK188778A A DK 188778AA DK 188778 A DK188778 A DK 188778A DK 148751 B DK148751 B DK 148751B
- Authority
- DK
- Denmark
- Prior art keywords
- cyclosporin
- isocyclosporin
- evaporated
- hereinafter
- vacuo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/911—Microorganisms using fungi
- Y10S435/945—Trichoderma
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/19—Antibiotic
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/27—Cyclic peptide or cyclic protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
i 148751
Den foreliggende opfindelse angår en fremgangsmåde til fremstilling af hidtil ukendte cyclosporinderivater med den almene formel I
CH3v /H3 CH C?3 /CH3 CH, CH, I Nh \V 3 CH, CH,I CH ,3 I 2 I 3I il CH,-N-CH-CO-N — CH- A — CO-N-CH-C-N-CH, 3 L L I L II I 2
„„CO H O CO
I I I
CH-CH,-CH l n-ch, 1 CH3/ 2 I 3
Η O H
I D L I L || L I L
OC-CH-N-CO-CH-N-CO-CH-N-C-CH-N-CO-CH
111 111 I
CH, H CH, CH, CH, CH CH, 3 3 .*2 V\ I 2
CH CH3 CH3 CH
ch3 nch3 ch3 ch3 hvor A betegner
CH, H
\y c 5 (i det nedenstående / \
H CH
betegnet cyclosporin D), i 2
e,,er HO _ CH
^cif ^CH,
f3 I
-C-N-CH —
II L
O
2 148751 CH3\ CH, I 2 H2C\
CH
I 2
IR
(i det nedenstående HØ ^
betegnet dihydro-cyclo- ^CH
sporin D), eller CH^ j 3 | N lH~ 0
CH, H
\ /
C
H CH,
(i det nedenstående |R
5 betegnet isocyclosporin D). 0 n CH
κ\κ/ \ XCH CH,
-C HN-CH
I 1 L
b ch3
Det er kendt, jfr. dansk fremlæggelsesskrift nr. 136.780 og beskrivelsen til dansk patentansøgning nr. 4831/76, at fremstille antibiotika betegnet cyclosporin A (også kendt som S 7481/F-1), cyclosporin B
3 148751 (også kendt som S 7481/F-2) og cyclosporin C ved dyrkning af en stamme af svampearten Trichoderma polysporum (Link ex. Pers) især NRRL 8044 og isolering af nævnte cyclosporiner fra kulturfiltratet.
Nævnte stamme indordnes nu under svampearten Tolypocladium infla-5 turn Cams. Cyclosporin A, B og C har immunoundertrykkende, betændelseshæmmende og arthritishæmmende virkning.
Det har nu overraskende vist sig, at ovennævnte svampeart ud over cyclosporin A, B og C danner en yderligere cyclosporin, nemlig cyclosporin D.
10 Fremgangsmåden ifølge den foreliggende opfindelse til fremstilling af de hidtil ukendte cyclosporin D, dihydro-cyclosporin D eller isocyclo-sporin D er i overensstemmelse hermed ejendommelig ved, at a) der ud fra et kulturfiltrat vundet ved dyrkning af en cyclospo-rin-producerende stamme af svampearten Tolypocladium inflatum Cams
15 isoleres cyclosporin D, hvorpå det vundne cyclosporin D
b) eventuelt hydrogeneres til dannelse af dihydro-cyclosporin D, eller c) eventuelt underkastes syrebehandling til dannelse af isocyclosporin D.
Til fremstillingen af cyclosporin D kan som nævnt anvendes stammer 20 af svampearten Tolypocladium inflatum Cams, fx NRRL 8044 eller sådanne, som kan fås ved selektion eller mutation af svampestammen NRRL 8044 ved påvirkning med ultraviolette stråler eller røntgenstråler eller under anvendelse af andre foranstaltninger, fx behandling af laboratoriekulturer med egnede kemikalier. 1
Cyclosporin D kan isoleres på i og for sig kendt måde, fx som beskrevet i eksempel 1. Herved kan cyclosporin D skilles fra samtidigt i store mængder tilstedeværende noget mere polært cyclosporin A, mere polært cyclosporin B og det endnu mere polære cyclosporin C.
4 148751
Det eventuelle fremgangsmådetrin b) ifølge den foreliggende opfindelse kan udføres på i og for sig kendte måder, fx ved katalytisk hydrogenering.
Som opløsningsmidler kan fortrinsvis anvendes lavere aliphatiske alko-5 holer, fx methanol, ethanol eller isopropanol, eller ethylacetat. Hydrogeneringen udføres hensigtsmæssigt ved neutral pH-værdi ved temperaturer mellem 20 og 30°C og ved atmosfæretryk eller ved svagt forhøjet tryk. Som katalysator anvendes fortrinsvis palladium, fx palladium/kul.
10 Syrebehandlingen ved det eventuelle fremgangsmådetrin c) kan udføres på i og for sig kendt måde, fx med trifluoreddikesyre, fortrinsvis med methansulfonsyre eller p-toluensulfonsyre.
Den til isomeriseringen anvendte mængde stærk syre ligger fortrinsvis mellem 1 og 4 mol pr. mol cyclosporin D.
15 Som opløsningsmidler kan fx anvendes lavere alkoholer, fx methanol, halogenerede carbonhydrider, fx chloroform, eller ethere, fx dioxan.
Reaktionstemperaturen kan variere mellem 20 og 65°C, fortrinsvis mellem 45 og 55°C.
Cyclosporin D, dihydro-cyclosporin D og isocyclosporin D udmærker 20 sig ved interessante kemoterapeutiske og farmakologiske egenskaber og kan derfor anvendes som lægemidler.
Cyclosporin D, dihydro-cyc.losporin D og isocyclosporin D er især indiceret ti| anvendelse som antiarthritica.
Cyclosporin D, dihydro-cyclosporin D og isocyclosporin D kan som 25 lægemidler administreres alene eller i en egnet lægemiddelform sammen med farmakologisk indifferente hjælpestoffer.
Fremgangsmåden ifølge den foreliggende opfindelse belyses nærmere ved følgende eksempler.
5 148751
EKSEMPEL 1 Cyclosporin D
500 liter af en næringsopløsning, som pr. liter indeholder 40 g glucose, 2,0 g natriumcaseinat, 2,5 g ammoniumphosphat, 5 g 5 MgSO^.THjO, 2 g KHjPO^, 3 g natriumnitrat, 0,5 g kaliumchlorid, 0,01 g FeSO^ og demineraliseret vand, podes med 50 liter af en forkultur af stamme NRRL 8044 og inkuberes i 13 dage ved 27°C i en stålfermenteringsbeholder under omrøring (170 OPM) og beluftning (1 liter luft/minut/liter næringsopløsning) (se tysk offentliggørelsesskrift 10 nr. 2.455.859).
Dyrkningsvæsken ekstraheres med en lige så stor mængde n-butylace-tat, den organiske fase skilles fra og inddampes i vakuum, og råekstrakten affedtes ved tre-trins-fordeling mellem methanol-vand (9:1) og petroleumsether. Den methanoliske fase fraskilles og inddampes i 15 vakuum, og råproduktet udfældes ved tilsætning af vand. Det ved filtrering vundne materiale chromatograferes på silicagel med hexan-acetone (2:1) som elueringsmiddel, hvorhos de først eluerede fraktioner overvejende indeholder cyclosporin A og cyclosporin D og de senere eluerede dele overvejende cyclosporin C. De cyclosporin A- og 20 D-holdige fraktioner krystalliseres til yderligere rensning af en 2 til 2,5 gange så stor mængde acetone ved -15°C, og det krystallinske materiale opspaltes derpå yderligere ved to gange chromatografi på silicagel, hvorhos de med vandmættet ethylacetat først eluerede fraktioner indeholder cyclosporin D i stærkt opkoncentreret form. Disse 25 opløses i en dobbelt så stor mængde acetone og lades krystallisere ved -15°C. Det således vundne rå krystallinske cyclosporin D opløses til videre rensning i en 10 gange så stor mængde acetone, der tilsættes 2 vægtprocent aktivt kul og opvarmes i 5 minutter til 60°C. Efter filtrering over talkum fås et klart og næsten farveløst filtrat, som 30 derpå inddampes til 1/3 af det oprindelige volumen og lades afkøle til stuetemperatur, hvorved cyclosporin D spontant udkrystalliserer. Ved henstand ved -17°C fuldendes krystalliseringen. Krystallerne frafil-treres og vaskes med lidt iskold acetone og tørres derpå i højvakuum ved 80°C i 2 timer.
20 148751 6
Karakterisering af cyclosporin D:
Farveløse, prismatiske krystaller, smeltepunkt 148-151°C, [ct]^ = -245° (c = 0,52 I chloroform), [α]ρ0 = -211° (c = 0,51 i methanol).
5 EKSEMPEL 2
Dihydro-cyclosporin D
400 mg palladium/kul (10%'s palladium) forhydrogeneres i 15 ml ethanol i 20 minutter. Til denne suspension af palladiumkatalysatoren sættes en opløsning af 3,66 g cyclosporin D opnået som i eksempel 1 i 30 ml 10 ethanol, og derpå hydrogeneres ved 24°C og et tryk på 736 mm Hg, til der ikke længere optages hydrogen. Derpå filtreres katalysatoren fra, og filtratet inddampes til tørhed i vakuum ved 20-30°C. Derved fås tyndtlagschromatografisk ensartet dihydro-cyclosporin D i form af et farveløst amorft pulver, som tørres i højvakuum i 4 timer ved 15 70°C.
Egenskaber for dihydro-cyclosporin D:
Smeltepunkt 153-156°C, [a]*° = -237° (c = 0,56 i CHCIg), [,«]q° = “196° (c = 0,58 i CHgOH).
20 EKSEMPEL 3
Isocyclosporin D
Til en opløsning af 18,25 g cyclosporin D opnået som i eksempel 1 i 120 ml absolut dioxan sættes en opløsning af 3,60 g methansulfonsyre i 60 ml dioxan, og blandingen holdes ved 50°C under fugtighedsude-25 lukkelse. Reaktionens forløb følges på tyndtlagschromatogram (Poly-
Claims (6)
148751 gram SIL G-folier, chloroform-methanol-iseddike (90:6:4), ioddamp til fremkaldelse). Efter 17 timer afkøles til stuetemperatur. Syren neutraliseres ved tilsætning af 3,38 g vandfrit natriumacetat, der omrøres i 15 minutter, 5 det udfældede salt isoleres ved sugefiltrering, og filtratet inddampes i vakuum ved 45°C. Remanensen (21 g) chromatograferes på 1,5 kg si-licagel, hvorhos der elueres med chloroform-methanol (98:2). De fraktioner, som praktisk taget består af rent isocyclosporin D, forenes og inddampes i vakuum ved 50°C, og remanensen krystalliseres to til tre 10 gange af ether, hvorved fås isocyclosporin D. Egenskaber for isocyclosporin D: Farveløse prismer, smeltepunkt 142-144°C. [o]p° = -205,5° (c = 0,51 i CHCIg), [a]p° = -144,4° (c = 0,64 i CHgOH).
15 PATENTKRAV Fremgangsmåde til fremstilling af cyclosporinderivater med den almene formel I CH3 /CH3 ''cH /CH3 CH-. CH3 I CH \V 3h |H2 ?H3| T I 3 CH,-N-CH-C0-N — CH- A — CO-N-CH-C-N-CH,
3. L I 1 li I 2 CO H O CO 3\ I I . CH-CH0-CH L N-CH, 1
2 I 3 CH3-·? Η O H i D L I L || L I L OC-CH-N-CO-CH-N-CO-CII-N-C-CH-N-CO-CH III III i CHj H CH3 CH2 CH3/CH CH2 CH CH3 CH3 CH CH3 Nch3 CH3 CH3 148751 hvor A betegner CH- H \/ C A |r2 . HO CH (i det nedenstående \ηχί CH betegnet cyclosporin D), CH_ I J I J d,er -C-N- CH —
11 L o CH3\ CH, 5 (i det nedenstående CH betegnet dihydro-cyclo- i 2 sporin D), eller H0 in \ R X \ ^CH CH- CH- I i3 I -C—N-CH- II o CH, H N / C II X\ H CH, I £ i R (i det nedenstående J,u κο η ^CH <;H -C HN-CH- t 1 L
0 CH3
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CH582377A CH628023A5 (en) | 1977-05-10 | 1977-05-10 | Process for the preparation of an antibiotic derivative |
CH582277A CH628022A5 (en) | 1977-05-10 | 1977-05-10 | Process for the preparation of an antibiotic derivative |
CH582277 | 1977-05-10 | ||
CH582377 | 1977-05-10 | ||
CH745777 | 1977-06-17 | ||
CH745777A CH632010A5 (en) | 1977-06-17 | 1977-06-17 | Process for the preparation of a novel antibiotic |
Publications (3)
Publication Number | Publication Date |
---|---|
DK188778A DK188778A (da) | 1978-11-11 |
DK148751B true DK148751B (da) | 1985-09-16 |
DK148751C DK148751C (da) | 1986-02-24 |
Family
ID=27175344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK188778A DK148751C (da) | 1977-05-10 | 1978-05-01 | Fremgangsmaade til fremstilling af cyclosporinderivater |
Country Status (17)
Country | Link |
---|---|
US (2) | US4220641A (da) |
JP (1) | JPS53139789A (da) |
AU (1) | AU526582B2 (da) |
CA (1) | CA1117046A (da) |
DE (1) | DE2819094A1 (da) |
DK (1) | DK148751C (da) |
ES (1) | ES469567A1 (da) |
FI (1) | FI59814C (da) |
FR (1) | FR2390420A1 (da) |
GB (1) | GB1591934A (da) |
IE (1) | IE46883B1 (da) |
IL (1) | IL54666A (da) |
IT (1) | IT1104195B (da) |
NL (1) | NL7804846A (da) |
PH (1) | PH13973A (da) |
PT (1) | PT68013B (da) |
SE (3) | SE438860B (da) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2907460A1 (de) * | 1978-03-07 | 1979-09-13 | Sandoz Ag | Neue resorbierbare galenische kompositionen |
SE448386B (sv) * | 1978-10-18 | 1987-02-16 | Sandoz Ag | Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem |
ATE43335T1 (de) * | 1980-02-14 | 1989-06-15 | Sandoz Ag | Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung. |
US4396542A (en) * | 1980-02-14 | 1983-08-02 | Sandoz Ltd. | Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production |
DE3260468D1 (en) * | 1981-01-09 | 1984-09-06 | Sandoz Ag | Novel cyclosporins |
US5639724A (en) | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
EP0365044A3 (en) * | 1984-08-02 | 1990-08-22 | Sandoz Ag | Novel pharmaceutical use of (nva)2-cyclosporine |
GB8422253D0 (en) * | 1984-09-04 | 1984-10-10 | Sandoz Ltd | Organic compounds |
DE3587505T2 (de) | 1984-10-04 | 1994-01-05 | Sandoz Ag | Monoklonale antikörper gegen zyklosporine. |
US4727035A (en) * | 1984-11-14 | 1988-02-23 | Mahoney Walter C | Immunoassay for cyclosporin |
US4764503A (en) * | 1986-11-19 | 1988-08-16 | Sandoz Ltd. | Novel cyclosporins |
US5427960A (en) * | 1987-03-27 | 1995-06-27 | Abbott Laboratories | Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies |
US5239057A (en) * | 1987-03-27 | 1993-08-24 | Abbott Laboratories | Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies |
US4798823A (en) * | 1987-06-03 | 1989-01-17 | Merck & Co., Inc. | New cyclosporin analogs with modified "C-9 amino acids" |
DE3851268T2 (de) * | 1987-06-19 | 1995-01-26 | Sandoz Ag | Zyklische Peptolide. |
EP0373260B1 (en) * | 1987-06-22 | 1994-03-09 | Merck & Co. Inc. | Cyclosporin derivatives with modified "8-amino acid" |
GB8717300D0 (en) * | 1987-07-22 | 1987-08-26 | Nat Res Dev | Cyclosporins |
US5227467A (en) * | 1987-08-03 | 1993-07-13 | Merck & Co., Inc. | Immunosuppressive fluorinated cyclosporin analogs |
DE3851152T2 (de) * | 1987-09-03 | 1995-01-26 | Univ Georgia | Cyclosporin-augenmittel. |
US4839342A (en) * | 1987-09-03 | 1989-06-13 | University Of Georgia Research Foundation, Inc. | Method of increasing tear production by topical administration of cyclosporin |
US5236899A (en) * | 1987-11-16 | 1993-08-17 | Merck & Co., Inc. | 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance |
US4914188A (en) * | 1987-11-16 | 1990-04-03 | Merck & Co., Inc. | Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin |
HU203564B (en) * | 1987-12-21 | 1991-08-28 | Sandoz Ag | Process for producing new orthorombos cyclosporin without solvatation |
HU201567B (en) * | 1988-07-21 | 1990-11-28 | Gyogyszerkutato Intezet | Process for production of intravenous medical compositions containing cyclosphorin |
US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
HU201577B (en) * | 1988-12-20 | 1990-11-28 | Gyogyszerkutato Intezet | Process for producing cyclosporin antibiotics |
US7081445B2 (en) * | 1989-02-20 | 2006-07-25 | Novartis Ag | Cyclosporin galenic forms |
US4996193A (en) * | 1989-03-03 | 1991-02-26 | The Regents Of The University Of California | Combined topical and systemic method of administration of cyclosporine |
US5540931A (en) * | 1989-03-03 | 1996-07-30 | Charles W. Hewitt | Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants |
GB8916901D0 (en) | 1989-07-24 | 1989-09-06 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5122511A (en) * | 1990-02-27 | 1992-06-16 | Merck & Co., Inc. | Immunosuppressive cyclosporin analogs with modified amino acids at position-8 |
EP0473961B1 (en) * | 1990-08-15 | 1996-01-03 | Abbott Laboratories | Immunoassay reagents and method for determining cyclosporine |
ATE158022T1 (de) * | 1991-01-25 | 1997-09-15 | Fujisawa Pharmaceutical Co | Prozess zur produktion von cyclosporin-a und/oder c |
ES2078374T3 (es) * | 1991-04-06 | 1995-12-16 | Dresden Arzneimittel | Procedimiento para la produccion por fermentacion y aislamiento de ciclosporina a, y nuevas cepas formadoras de ciclosporina. |
GB9204466D0 (en) * | 1992-03-02 | 1992-04-15 | Sandoz Ltd | Improvements in or relating to organic compounds |
EP0725076B1 (en) * | 1995-02-01 | 2001-06-06 | National Research Development Corporation of India | A process for the preparation of cyclosporin A from tolypocladium species |
CN1079837C (zh) * | 1995-02-28 | 2002-02-27 | 国家研究发展公司 | 从分枝层壁菌制备环胞多肽a的方法 |
US5827822A (en) * | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5766629A (en) | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5962019A (en) * | 1995-08-25 | 1999-10-05 | Sangstat Medical Corporation | Oral cyclosporin formulations |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5747330A (en) * | 1996-06-05 | 1998-05-05 | Poli Industria Chimica | Antibiotic producing microbe |
DE29824679U1 (de) | 1997-01-30 | 2002-03-28 | Novartis Ag, Basel | Pharmazeutische Zusammensetzungen |
IN188719B (da) * | 1997-09-08 | 2002-11-02 | Panacea Biotec Ltd | |
US6187747B1 (en) | 1997-09-08 | 2001-02-13 | Panacea Biotech Limited | Pharmaceutical composition comprising cyclosporin |
US6346511B1 (en) | 1997-09-08 | 2002-02-12 | Panacea Biotec Limited | Pharmaceutical composition comprising cyclosporin |
US6008191A (en) * | 1997-09-08 | 1999-12-28 | Panacea Biotec Limited | Pharmaceutical compositions containing cyclosporin |
KR100585348B1 (ko) | 1997-10-08 | 2006-06-01 | 이소테크니카 인코포레이티드 | 중수소화된 시클로스포린 유사체 및 면역조절제로서 그의용도 |
US20030220234A1 (en) * | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
JP4350898B2 (ja) | 1998-07-01 | 2009-10-21 | デビオファーム・ソシエテ・アノニム | 活性の特徴が改善された新規のシクロスポリン |
NZ531944A (en) * | 2001-10-19 | 2006-03-31 | Isotechnika Inc | Synthesis of cyclosporin analogs |
EP1435910B9 (en) * | 2001-10-19 | 2010-02-03 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
EP1809656A4 (en) | 2004-09-29 | 2009-03-25 | Amr Technology Inc | CYCLOSPORINAL KINANALOGA AND ITS PHARMACEUTICAL APPLICATIONS |
WO2006041631A2 (en) | 2004-10-06 | 2006-04-20 | Amr Technology, Inc. | Novel cyclosporin alkynes and their utility as pharmaceutical agents |
US10137083B2 (en) * | 2006-03-07 | 2018-11-27 | SGN Nanopharma Inc | Ophthalmic preparations |
US11311477B2 (en) | 2006-03-07 | 2022-04-26 | Sgn Nanopharma Inc. | Ophthalmic preparations |
US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
WO2008036244A1 (en) * | 2006-09-18 | 2008-03-27 | The Burham Institute For Medical Research | Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands |
TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
NZ594755A (en) * | 2009-01-30 | 2013-12-20 | Enanta Pharm Inc | Cyclosporin analogues for preventing or treating hepatitis c infection |
US8481483B2 (en) * | 2009-02-19 | 2013-07-09 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8367053B2 (en) * | 2009-07-09 | 2013-02-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8349312B2 (en) * | 2009-07-09 | 2013-01-08 | Enanta Pharmaceuticals, Inc. | Proline substituted cyclosporin analogues |
US8685917B2 (en) * | 2009-07-09 | 2014-04-01 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues |
US8623814B2 (en) * | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
HUE042490T2 (hu) | 2010-12-15 | 2019-07-29 | Contravir Pharmaceuticals Inc | 1-es és 3-as aminosav-pozícióban módosított ciklosporin analóg molekulák |
CA2852056C (en) | 2011-03-11 | 2021-08-10 | Beth Israel Deaconess Medical Center, Inc. | Anti-cd40 antibodies and uses thereof |
WO2012145427A1 (en) | 2011-04-18 | 2012-10-26 | The Trustees Of Columbia University In The City Of New York | Methods to treat cancer using cyclosporine and cyclosporine derivatives |
US8906853B2 (en) | 2012-11-28 | 2014-12-09 | Enanta Pharmaceuticals, Inc. | [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection |
CA2921961A1 (en) | 2013-08-26 | 2015-03-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c |
US9669095B2 (en) | 2014-11-03 | 2017-06-06 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis C infection |
AU2016315873B2 (en) | 2015-09-04 | 2022-08-18 | Primatope Therapeutics Inc. | Humanized anti-CD40 antibodies and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4838877B1 (da) * | 1970-06-30 | 1973-11-20 | Toyo Jozo Kk | |
CH614931A5 (da) * | 1975-11-04 | 1979-12-28 | Sandoz Ag | |
US4215199A (en) * | 1978-06-05 | 1980-07-29 | Sandoz Ltd. | Antibiotic production |
-
1978
- 1978-04-29 DE DE19782819094 patent/DE2819094A1/de active Granted
- 1978-05-01 DK DK188778A patent/DK148751C/da not_active IP Right Cessation
- 1978-05-02 SE SE7805055A patent/SE438860B/sv not_active IP Right Cessation
- 1978-05-02 FI FI781348A patent/FI59814C/fi not_active IP Right Cessation
- 1978-05-04 US US05/902,794 patent/US4220641A/en not_active Expired - Lifetime
- 1978-05-05 IT IT49208/78A patent/IT1104195B/it active
- 1978-05-05 NL NL7804846A patent/NL7804846A/xx not_active Application Discontinuation
- 1978-05-08 IL IL54666A patent/IL54666A/xx unknown
- 1978-05-08 IE IE932/78A patent/IE46883B1/en unknown
- 1978-05-08 PH PH21111A patent/PH13973A/en unknown
- 1978-05-08 PT PT68013A patent/PT68013B/pt unknown
- 1978-05-08 GB GB6316/80A patent/GB1591934A/en not_active Expired
- 1978-05-08 ES ES469567A patent/ES469567A1/es not_active Expired
- 1978-05-09 CA CA000302914A patent/CA1117046A/en not_active Expired
- 1978-05-09 FR FR7813625A patent/FR2390420A1/fr active Granted
- 1978-05-09 AU AU35947/78A patent/AU526582B2/en not_active Expired
- 1978-05-09 JP JP5412578A patent/JPS53139789A/ja active Granted
-
1980
- 1980-03-03 US US06/126,215 patent/US4289851A/en not_active Expired - Lifetime
-
1984
- 1984-03-01 SE SE8401135A patent/SE8401135L/sv not_active Application Discontinuation
- 1984-03-01 SE SE8401134A patent/SE8401134L/sv not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL54666A0 (en) | 1978-07-31 |
US4220641A (en) | 1980-09-02 |
SE7805055L (sv) | 1978-11-11 |
IT7849208A0 (it) | 1978-05-05 |
PT68013A (fr) | 1978-06-01 |
ES469567A1 (es) | 1980-01-01 |
DK148751C (da) | 1986-02-24 |
DK188778A (da) | 1978-11-11 |
PT68013B (fr) | 1980-03-05 |
IE46883B1 (en) | 1983-10-19 |
FI59814C (fi) | 1981-10-12 |
SE8401134D0 (sv) | 1984-03-01 |
JPS6252760B2 (da) | 1987-11-06 |
CA1117046A (en) | 1982-01-26 |
JPS53139789A (en) | 1978-12-06 |
IL54666A (en) | 1980-12-31 |
FR2390420B1 (da) | 1980-10-31 |
AU526582B2 (en) | 1983-01-20 |
FI59814B (fi) | 1981-06-30 |
PH13973A (en) | 1980-11-20 |
AU3594778A (en) | 1979-11-15 |
SE8401135D0 (sv) | 1984-03-01 |
SE8401135L (sv) | 1984-03-01 |
FR2390420A1 (fr) | 1978-12-08 |
GB1591934A (en) | 1981-07-01 |
SE8401134L (sv) | 1984-03-01 |
DE2819094C2 (da) | 1988-11-03 |
US4289851A (en) | 1981-09-15 |
FI781348A (fi) | 1978-11-11 |
SE438860B (sv) | 1985-05-13 |
NL7804846A (nl) | 1978-11-14 |
IE780932L (en) | 1978-11-10 |
DE2819094A1 (de) | 1978-11-23 |
IT1104195B (it) | 1985-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK148751B (da) | Fremgangsmaade til fremstilling af cyclosporinderivater | |
DK148752B (da) | Fremgangsmaade til fremstilling af cyclosporinderivater | |
FI60701C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbar dihydrocyklosporin c | |
EP0109047B1 (en) | Total synthesis of antitumor antibiotics | |
US5389639A (en) | Amino alkanoic esters of rapamycin | |
Yamagishi et al. | Antitumor agents, 110, Bryophyllin B, a novel potent cytotoxic bufadienolide from Bryophyllum pinnatum | |
US5385909A (en) | Heterocyclic esters of rapamycin | |
US5221670A (en) | Rapamycin esters | |
US5922730A (en) | Alkylated rapamycin derivatives | |
US5457194A (en) | Substituted aliphatic amine-containing macrocyclic immunomodulators | |
EP0549727A1 (en) | Carboxylic acid esters of rapamycin | |
EP0011276A1 (en) | Maytansinoids, their production and use | |
DK162647B (da) | Fremgangsmaade til fremstilling af pyrido-imidazorifamyciner | |
JP2008532991A (ja) | ラパマイシンの39−デスメトキシ誘導体 | |
JPH04211699A (ja) | 8位に変性アミノ酸を有する新規な免疫抑制シクロスポリン類縁体 | |
HUT70207A (en) | 21-norrapamycin, pharmaceutical compositions containing it and process for preparing them | |
US5541189A (en) | Substituted aliphatic amine-containing macrocyclic immunomodulators | |
CA2266039A1 (en) | Alkylated rapamycin derivatives | |
NO128710B (da) | ||
US5530119A (en) | Substituted alicyclic amine-containing macrocyclic immunomodulators | |
EP0855398B1 (en) | Sesquiterpene derivatives having antiviral activity | |
US4226856A (en) | Preparation and use of bouvardin and deoxybouvardin | |
US3944582A (en) | Carbamates of ergolines | |
US5530120A (en) | Substituted alicyclic aliphatic-amine containing macrocyclic immunomodulators | |
US4251529A (en) | Ergot peptide alkaloids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PBP | Patent lapsed |